Br J Clin Pharmacol. 2007 Jul;64(1):3-13. Epub 2007 Feb 23.

Population pharmacokinetic and pharmacodynamic models of remifentanil in healthyvolunteers using artificial neural network analysis.

Kang SH, Poynton MR, Kim KM, Lee H, Kim DH, Lee SH, Bae KS, Linares O, Kern SE, Noh GJ.

Abstract

AIMS:

An ordinary sigmoid E(max) model could not predict overshoot of electroencephalographic approximate entropy (ApEn) during recovery from remifentanil effect in our previous study. The aim of this study was to evaluate the ability of anartificial neural network (ANN) to predict ApEn overshoot and to evaluate the predictive performance of the pharmacokineticmodel, and pharmacodynamic models of ANN with respect to data used.

METHODS:

Using a reduced number of ApEn instances (n = 1581) to make NONMEM modelling feasible and complete ApEn data (n = 24 509), the presence of overshoot was assessed. A total of 1077 measured remifentanil concentrations and ApEn data, and a total of 24 509 predicted concentrations and ApEn data were used in the pharmacodynamic model A and B of ANN, respectively. The testing subset of model B (n = 7352) was used to evaluate the ability of ANN to predict overshoot of ApEn. Mean squared error (MSE) was calculated to evaluate the predictive performance of the ANN models.

RESULTS:

With complete ApEn data, ApEn overshoot was observed in 66.7% of subjects, but only in 37% with a reduced number of ApEn instances. The ANN model B predicted 77.8% of ApEn overshoot. MSE (95% confidence interval) was 57.1 (3.22, 71.03) for the pharmacokinetic model, 0.148 (0.004, 0.007) for model A and 0.0018 (0.0017, 0.0019) for model B.

CONCLUSIONS:

The reduced ApEn instances interfered with the approximation of true electroencephalographic response. ANN predicted 77.8% of ApEn overshoot. The predictive performance of model B was significantly better than that of model A.